Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Immunogenicity of Cholesterol-Bearing Hydrophobized Pullulan HER2 Protein 146 (CHP-HER2) and NY-ESO-1 Protein (CHP-NY-ESO-1) in Combination With OK-432 [picibanil] in HER2- and/or NY-ESO-1-Expressing Cancers

Next Previous
Trial Profile

Safety and Immunogenicity of Cholesterol-Bearing Hydrophobized Pullulan HER2 Protein 146 (CHP-HER2) and NY-ESO-1 Protein (CHP-NY-ESO-1) in Combination With OK-432 [picibanil] in HER2- and/or NY-ESO-1-Expressing Cancers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cancer vaccines (Primary)
  • Indications Breast cancer; Gastric cancer; Lung cancer; Oesophageal cancer; Ovarian cancer
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

Most Recent Events

  • 03 Mar 2009 Biomarkers information updated
  • 28 Jan 2009 Status changed from suspended to completed as reported by ClinicalTrials.gov.
  • 07 May 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top